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Abstract
COVID-19 pandemic caused by SARS-COV-2 virus has evolved into a global 
crisis and is a major concern especially for the diabetes community. People 
with diabetes mellitus have increased morbidity and mortality associated with 
COVID-19 infection. Conversely, COVID-19 infection and treatment may pre-
dispose to hyperglycemia. Potentially modifiable risk factors have been discussed 
and urgent need to mitigate the risks is warranted. In this book chapter we 
summarize the available evidence on COVID-19 and type 2 diabetes mellitus 
including link between COVID-19 and type 2 diabetes, pathophysiology, clinical 
manifestations, management and complications.
Keywords: COVID-19, SARS-COV-2, diabetes mellitus, hyperglycaemia,  
type 2 diabetes
1. Introduction
From the offset of Coronavirus disease (COVID-19), groups that are more 
vulnerable to COVID-19 were identified. Presence of diabetes mellitus (DM), both 
type 1 (T1DM) and type 2 (T2DM) independently increases the adverse effects of 
COVID-19 [1]. A meta-analysis found that the proportion of diabetes in COVID-19 
patients was 9.7% and that having cardiac disease and diabetes increased the risk of 
death by twice as much as the other risk factors [2]. The purpose of this chapter is 
to discuss in detail the current evidence available regarding type 2 diabetes mellitus 
and COVID-19.
2. Pathophysiology of T2D and COVID-19
There has been some insight into the pathophysiological mechanisms of 
COVID-19 infection and diabetes, but much remains to be investigated. The SARS-
CoV2 utilizes angiotensin converting enzyme 2 (ACE2) to gain entry into infected 
cells and reduces expression of ACE2, and over activation of renin angiotensin 
aldosterone system (RAAS) is proposed to contribute to adverse effects in patients 
with diabetes (PWD) and COVID-19 infection [3].
Mechanisms accentuated in PWD include increased inflammatory cytokines, 
increased lipopolysaccharides, and increased RAAS (angiotensin 2) which results in 
vascular endothelial damage, increased ROS and IL-6 in increased insulin resistance 
(due to exaggerated angiotensin 2 activity) which results in hyperglycaemia [4]. 
There is increased blood viscosity due to increased fibrinogen and d-dimer [4]. 
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The S1 spike protein of SARS-Cov2 is predicted to bind to DPP4 which may facili-
tate epithelial infection [1, 5].
It has been noted that infection with SARS-Cov-2 virus results in damage to 
pancreatic beta-cells [6]. Apart from COVID-19 related impaired insulin produc-
tion [7], COVID-19 can cause insulin resistance due to activation of integrated 
stress response (ISR) initiating serine/threonine kinases which can induce IRS-1 
serine phosphorylation. Hence, patients with COVID-19 infection can present with 
hyperglycaemia for the first time and may require insulin for insulin naïve patients 
or the one on insulin may have increased requirements [8].
Patients with type 2 diabetes (T2D) have a dysregulated immune response with 
higher ratio of lymphopenia, and increased levels of neutrophils, CRP and IL-6 
have been noted in PWD with COVID-19 infections. T2D is associated with activa-
tion of the RAAS in different tissues [3]. In PWD pulmonary dysfunction has been 
reported involving changes in lung volume, lung diffusing capacity, ventilation, 
bronchomotor tone and neuroadrenergic bronchial innervation [3].
Increased metabolic rate, dysregulation of glucose metabolism, aggravation of 
inflammation and immune modulation result in increased oxidative stress, cytokine 
production, endothelial damage, increased glucotoxicity which ultimately can 
result in increased severity of COVID-19 and rapid progression of cardiorespiratory 
failure [4].
3. Clinical manifestations
The most common symptoms of COVID-19 infection are fever, cough [9], 
fatigue and shortness of breath [10]. Other symptoms such as sore throat, rhinor-
rhoea, ageusia, anosmia, vomiting and diarrhea have also been reported [11]. An 
observational study noted that male patients were more vulnerable than female 
patients to COVID-19 infection [9]. Common comorbidities include diabetes  
mellitus, hypertension obesity and cardiovascular disease [10].
Multiple comorbidities are associated with more severe disease and higher 
mortality [9]. Patients with T2D are more likely to develop severe COVID-19 infec-
tion as compared with patients without diabetes [12]. An increased prevalence of 
chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD) 
has been noted in patients with T2D and COVID-19 infection [11]. COVID-19 
infection may result in severe insulin resistance and insulin deficiency precipitating 
diabetic ketoacidosis (DKA) in patients with T1DM and not commonly but still pos-
sible in T2DM, result in new onset diabetes, or in PWD result in new or increased 
insulin therapy at times with very high dose requirements. Dexamethasone therapy 
which has been found to be beneficial in COVID-19 infection, can result in further 
hyperglycaemia and has the potential of precipitating Hyperosmolar hypergly-
caemic state (HHS) and DKA [7]. Regular monitoring of capillary blood glucose 
(CBGs) is warranted for inpatients. As hyperglycaemia with ketosis may occur 
in COVID-19 infection, ketones should be checked in all patients with diabetes 
initially or if CBG > 12 mmol/L [13].
Laboratory findings include lymphopenia, thrombocytopenia, raised CRP, 
raised ALT and other markers of inflammation such as ferritin [10]. Compared 
with patients without diabetes, patients with T2DM were found to have a higher 
ESR, CRP, IL-6, TNF-α and procalcitonin but lower lymphocyte and T lymphocyte 
subsets [12]. HbA1C, IL-6 and lymphocyte count have been proposed as risk fac-
tors for the severity of COVID-19 infection and T2DM [12]. CT scan changes are 
common and include ground glass abnormalities, lung lesions and enlargement of 
lymph nodes [10].
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4. Management of type 2 diabetes and COVID-19 infection
Diabetes UK, a British-based patient, healthcare professional and research 
charity, has provided advice for healthcare professionals on COVID-19 and inpa-
tient diabetes care on their website and topics include front door guidance, manag-
ing inpatient hyperglycaemia, dexamethasone therapy and safe discharge endorsed 
by the Joint British Diabetes Society (JBDS) and Association of British Clinical 
Diabetologists (ABCD) [14].
Front door guidance is available for inpatients [13]. An ABCDE (Airway, 
breathing, circulation, disability and exposure) approach is warranted initially if 
patient is unwell, CBG> 12 mmol/L or known diabetes. Aim is rule out DKA, HHS 
and watch out for new presentation of diabetes, sepsis, steroid use, uncontrolled 
diabetes or delayed and missed treatment of diabetes [13]. Be aware of the pos-
sibility of euglycaemic DKA. Stop Metformin and SGLT2 inhibitors on admission. 
Fluid requirements may differ in patients with COVID-19 infection and have 
to be tailored individually due to ARDS, cardiac involvement or AKI. Contact 
the diabetes specialist team and early involvement of critical care team where 
appropriate.
Target glucose levels are 6–10 mmol/L, and up to 12 mmol/L is acceptable. The 
guidance for managing inpatient hyperglycaemia should be used if glucose levels 
are >12 mmol/L and a corrective dose is appropriate and the patient is not in DKA 
or HHS [14]. It provides information for patients on insulin and insulin naïve 
patients too, regarding insulin dose adjustment as while recovering from COVID-19 
related insulin resistance, doses may require rapid reduction to avoid hyperglycemia 
[14]. Initiation of IV insulin with monitoring of blood glucose, electrolytes, pH and 
ketones should be done as appropriate. Blood ketones <0.6 mmol/L is safe, blood 
ketones 1.5–2.9 mmol/L signifies increased risk of DKA [13], and if 3 mmol/L or 
greater, then check pH and bicarbonate for possibility of DKA [13].
If patients unable to manage insulin pump start on variable rate intravenous 
insulin infusion (VRII) or subcutaneous (S/C) insulin. For S/C insulin find out the 
total daily insulin dose and if not available can be calculated as 0.5 units multiplied 
by weight. Half this dose is given as basal and remaining half as bolus dose divided 
by 3 to give the meal time dose [13]. If patient is placed in prone position, feeding 
may be affected and that needs to be taken into account while dosing insulin.
Continuous glucose monitors (CGMs) and flash glucose monitoring (FGM) can 
be left on but capillary blood glucose monitoring must still continue. For magnetic 
imaging such as MRIs, these devices including pumps should be removed [13]. 
Always check the feet on admission to look for foot infection and rule out critical 
limb ischaemia.
4.1 Medications used in diabetes
As it was not feasible to conduct RCTs initially, expert opinion and observational 
studies regarding treatment with medication for T2D suggest the following [15]:
Regular monitoring blood glucose of patients on insulin should be encour-
aged [15]. A retrospective study in patients in China found that patients with T2D 
required more medical interventions and had a significantly higher mortality and 
multiple organ injury than the non-diabetic individuals [3]. Within PWD they 
found that well controlled BG (CBG 3.9–10 mmol/L) was associated with reduction 
in adverse outcomes including lower mortality as compared with poorly controlled 
BG while in hospital. Hence correlation of improved glycaemic control with better 
outcomes was made and aggressive blood glucose lowering treatment with tablets 
and insulin was advocated.
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4.1.1 Insulin
Insulin therapy is the mainstay in acute unwell PWD admitted to hospital 
where oral tablets have been stopped or not enough to control the hyperglycae-
mia. However, there is some evidence that insulin treatment is associated with 
adverse clinical outcomes in patients with T2D and COVID-19, including increased 
mortality. Use of insulin was associated with enhanced inflammation (increased 
IL-1β-dependent CRP and IL-6) and injury of vital organs (acute cardiac injury 
and acute kidney injury) during the progression of COVID-19 in patients with T2D 
[16]. Hypoglycaemia was higher in patients on insulin and may have contributed 
to the increased mortality although a sub-group without hypoglycaemia still had 
increased mortality. Insulin has been the mainstay in ill PWD and if hyperglycae-
mia and insulin result in adverse outcomes, there is a difficult dilemma for clinicians 
[17]. A UK study of 2.85 million PWD, a higher risk of COVID-19 related mortality 
was seen in patients on insulin, but the higher risk was thought to be due to residual 
confounding factors rather than direct drug effects [18]. Currently guidelines 
continue to endorse insulin in unwell PWD. Caution and close monitoring is to be 
exerted while using insulin treatment in PWD and COVID-19.
4.1.2 Metformin
Metformin, a lipophilic biguanide, has been associated with reduced mortality 
in women with obesity or T2D admitted to hospital with COVID-19 infection [19]. 
Several explanations have been provided including decreased inflammatory factors. 
Retrospective studies evaluating use of Metformin in T2D and COVID-19 infection 
have mainly suggested some benefit or no harm or benefit whereas a single study 
has suggested some harm, but overall use of Metformin is considered to be safe 
[20]. The CORONADO study which was a prospective study noted that Metformin 
was associated with a lower risk of death in PWD hospitalized with COVID-19 
infection [21]. Dehydration with Covid-19 may increase the risk of lactic acidosis in 
patients taking metformin, hence temporary cessation of the drug along with usual 
sick day rules should be followed. Renal function should be monitored closely [15]. 
As metformin may reduce progression to severe COVID-19 infection, after initial 
cessation and review of clinical parameters including hypoxic state, lactate and 
renal parameters, metformin may be re-introduced if appropriate [13]. The MET-
Covid Trial is an RCT designed to evaluate use of Metformin versus placebo for 
outpatient treatment and post exposure prophylaxis of COVID-19 infection [22].
4.1.3 Sodium glucose co-transporter 2 inhibitors
Sodium glucose co-transporter 2 inhibitors (SGLT2i) primarily act on the proxi-
mal tubule to block sodium and glucose absorption. Given that the mechanisms that 
are attributed to the protective effects of SGLT2i overlap with the mechanisms that 
are activated in COVID-19 infection, SGLT2i seem to have the potential to protect 
against end organ damage through cardio-renal protection [23]. Initiation of this 
medication should not be done during any likely infection, and for patients with 
T2D with COVID-19 infection, on SGLT2I, risk of dehydration and euglycemic DKA 
remains and should temporarily stop this medication and follow sick day rules. Renal 
function should be monitored closely [15]. A retrospective study to evaluate SGLT2i 
and COVID19 infection in a large UK based primary care dataset concluded that as 
compared to DPP4i, SGLT2i did not confer an increased risk of COVID-19 infection 
[24]. They deemed that clinicians can safely use SGLT2i the everyday care of PWD 
during COVID-19. DARE-19, is the first randomized controlled multi-centre trial 
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investigating the use of Dapagliflozin, and the goals are to prevent COVID-19 related 
organ dysfunction or mortality and to improve clinical recovery [23].
4.1.4 Glucagon like peptide receptor agonists
Glucagon like peptide receptor agonist (GLP-1 RA) in animal studies has shown 
to activate ACE-2 expression and there have been speculations if this accelerated 
virus entrance into host cells but also if this expression neutralizes the virus limiting 
infection [25]. There is support for the hypothesis that GLP-1 RA may mitigate a 
more adverse clinical course in PWD and COVID-19 infection [26]. GLP-1 RA also 
are beneficial with weight loss. There are a few studies on GLP1RA and COVID-
19 infection and even the final report of the CORONADO study did not find any 
benefit or harm with its use [27]. Dehydration is likely to lead to serious illness so 
patients on GLP1RA with COVID-19 should be monitored [15]. Regular meals and 
adequate hydration should be encouraged [15].
4.1.5 Dipeptidyl peptidase-4 inhibitors
It has been proposed that SARS Cov-2 binds to Dipeptidyl peptidase-4 inhibitors 
(DPP4), but the clinical implications are not known. Dipeptidyl peptidase-4 inhibi-
tors (DPP4i) are well tolerated in COVID-19 infection [15]. The majority of studies 
have shown either benefit with DPP4i in PWD and COVID-19, or no harm or benefit 
[20], Although DPP4 inhibitors appear to be safe in T2D and COVID-19 infection 
[4], in an observational study of 717 patients, in the diabetes sub-group, patients on 
DPP4I were at a higher risk of ICU admission [5]. As study that compared GLP-1 RA 
or DPP4i with SGLT2i did not note associated improved outcomes in patients with 
COVID-19 infection [28]. As DPP4 upregulation may be an indicator for severity of 
COVID-19 infection, there is interest regarding the use of DPP4i in COVID-19 infec-
tion and available information may form the path to discovering novel therapies 
[29]. RCTs involving Linagliptin versus placebo and Sitagliptin versus placebo have 
been registered [30, 31].
4.1.6 Sulphonylureas
The use of sulphonylureas with regard to COVID-19 infection has not shown 
any harm or benefit according to some retrospective studies [20]. If there is a risk 
of hypoglycaemia, they may be stopped. Sulphonylureas are not recommended in 
the context of dexamethasone induced hyperglycaemia as beta cell function maybe 
impaired with COVID-19 infection and there is insulin resistance too [7].
4.1.7 Thiazolidinediones
Several studies have shown a reduction in proinflammatory cytokines with 
pioglitazone, but no studies have reported outcomes in pioglitazone users with 
COVID-19 infection, and due to small numbers of users meaningful data is unlikely 
to be available soon [20].
4.1.8 Steroid induced hyperglycaemia
Dexamethasone has been proven to reduce mortality in patients dependent on 
oxygen therapy and ventilation. However, recommended dose of 6 mg orally or 
intravenously are bound to affect glucose metabolism and guidance for glucocorti-
coid therapy in patients with and without diabetes is provided by DUK [14].
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4.2 Hypertension
Treatment with angiotensin-converting enzyme inhibitors (ACEI) and angio-
tensin receptor blockers (ARBs) could increase the expression of ACE2 and acceler-
ate entry of the virus into the cells. However, in COVID-19 infection, impairment of 
the ACE2/Mas receptor pathway and increase in angiotensin-2 activity could occur, 
and RAAS blockade may protect against this serious lung injury. Thus it is recom-
mended that ACEI and ARBs should continue [15].
4.3 Lipid medications
Reduction on ACE2 by hyperlipidemia is restored by statins. It is believed that statins 
should not be discontinued in patients with COVID-19 infection due to it pleiotropic 
effects and potential for a cytokine storm due to rebound increase in interleukins [15].
4.4 Renal transplant recipients
Potential effect of COVID-19 on pancreatic function of patients with solid organ 
transplants is not known. Monitoring is required for patients with PTDM and 
without diabetes at risk of PTDM [15].
4.5 Fatty liver disease
Should be considered at an increased risk of cytokine storm and should be con-
sidered at risk of severe disease. Hence patients at risk of a cytokine storm and are 
to be considered at an increased risk of severe disease. There may be some benefit of 
screening and monitoring tests for hyperinflammation [15].
4.6 Discharge
Advice regarding safe and supported discharge is available [14]. Patients using 
insulin pumps or wearable diabetes technology should have them returned to the 
patient if not being used and ensure enough consumables are available at home. If a 
patient has had DKA, SGLT2i should not be used. Metformin can be re-started once 
the patient is well, eGFR>30 ml/min and lactate is normal. Sulphonylureas may 
have been withheld due to risk of hypoglycaemia, and assessment should be made if 
re-starting it is appropriate.
4.7 Outpatient management
It is suggested that patients with diabetes (PWD) not yet infected with the 
SARS-CoV-2 virus should intensify their treatment to prevent COVID-19 infection 
including glycaemic control, management of hypertension and raised cholesterol. 
Tele medicine and virtual appointments should continue to ensure adequate follow 
up [15]. The priority was to contain spread of COVID-19 but health care services 
need to ensure that the needs of PWD are met is imperative which includes continu-
ous supply of medications and available healthcare services in the primary care [32].
4.8 Prevention
Patients with COVID-19 infection without diabetes should be monitored for 
new onset diabetes especially if on steroids. PWD and COVID-19 infection should 
have good glycaemic control [15].
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4.9 Lifestyle management
While lockdown was the best armamentarium we had while the vaccination 
program was established and rolled out, it lead to potential for more sedentary 
activity, unhealthy diet, mental health related issues and possible delay in seek-
ing care due to fear of contracting COVID-19 especially for patients with chronic 
conditions. Maintaining a healthy lifestyle is important now more than ever [32]. 
Adoption of dietary advice and restriction of dietary carbohydrates has been 
proposed for people with metabolic syndrome [33]. Smoking was associated with a 
higher mortality rate in hospitalized patients and advice regarding smoking cessa-
tion should be given [9].
4.10 Prediabetes
Prediabetes is associated with increased CRP and IL-6, and hospitalized patients 
with moderate to severe COVID-19 infection have been noted to have prediabe-
tes, hence it has been proposed that pre-diabetes be treated as a comorbidity for 
COVID-19 infection [34]. Whether screening of all COVID-19 infected patients for 
prediabetes to improve patient care is feasible or beneficial remains to be seen as 
there is currently no therapeutic drug approved for prediabetes.
5. Complications
Apart from the known pulmonary complications, extra pulmonary complica-
tions from COVID-19 include neurological, cardiovascular, gastro-intestinal, 
renal, endocrine and dermatological complications are being reported [35]. Due 
to COVID-19 infection, there have been increased risk of hyperglycaemia, eugly-
caemic ketosis and diabetic ketoacidosis (DKA) [35]. With COVID-19 infection, 
there is a risk of atypical presentations of complications such as DKA or mixed 
hyperosmolar states with associated increased mortality. A retrospective case series 
confirmed that PWD are at a risk of combined DKA and HHs with COVID-19 
infection [36]. Data from our own centre has shown that DKA in T2DM is increased 
significantly and that the frequency of HHS increased seven fold during the first 
Covid pandemic in the UK [37]. Fluid management is a challenge in such patients 
especially in case of renal impairment and ARDS should be avoided. Guidelines 
for management of DKA is available on the Diabetes UK website and it is worth 
remembering that euglycaemic DKA can occur in patients taking SGLT2i or in 
pregnancy [14]. In a whole population study assessing risks of in-hospital death in 
England, people with T1DM were found to be three-and-a-half times more at risk 
of dying from COVID-19 infection, while people with T2D are at twice the risk of 
dying than people without diabetes [38]. Hence, continued measures to mitigate the 
risks of people with diabetes of becoming seriously ill or dying due to COVID-19 
infection is warranted.
6. Conclusion
COVID-19 infection and diabetes mellitus have important and clinically relevant 
interactions. It is important for all physicians to be aware of these, particularly in 
view of likely further COVID-19 pandemics.
Fighting the COVID-19 Pandemic
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